Suchergebnisse - "Roeker, Lindsey E"

PubPharm (11)

1

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings : Results From a Multi-Center International Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Shadman, M. | Manzoor, B. | Sail, K. | +28

2

Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States : a real-world database study

enthalten in: Leukemia & lymphoma | 2023

von Eyre, T. | Hess, L. | Sugihara, T. | +8

3

MAJIC : a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

enthalten in: Future oncology (London, England) | 2022

von Ryan, C. | Davids, M. | Hermann, R. | +7

ErratumIn: Future Oncol. 2023 Jan;19(3):271. - PMID 36655699

4

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

enthalten in: Blood advances | 2022

von Thompson, M. | Harrup, R. | Coombs, C. | +35

5

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Soumerai, J. | Mato, A. | Dogan, A. | +43

CommentIn: Lancet Haematol. 2021 Dec;8(12):e864-e865. - PMID 34826404

6

Approaches for relapsed CLL after chemotherapy-free frontline regimens

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von Roeker, L. | Mato, A.

7

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Mato, A. | Roeker, L. | Jacobs, R. | +51

CommentIn: Clin Cancer Res. 2020 Jul 15;26(14):3501-3502. - PMID 32366672

8

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

enthalten in: British journal of haematology | 2020

von Eyre, T. | Roeker, L. | Fox, C. | +22

9

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Roeker, L. | Fox, C. | Eyre, T. | +33

10

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

enthalten in: Blood advances | 2019

von Mato, A. | Roeker, L. | Eyre, T. | +35